Unveiling the Knowledge Frontier: A Scientometric Analysis of COPD with Sarcopenia

References

• Soriano JB, Kendrick PJ, Paulson KR, et al. Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet Respir Med. 2020;8(6):585–596. doi:10.1016/s2213-2600(20)30105-3
   PubMed Web of Science ®Google Scholar
• Christenson SA, Smith BM, Bafadhel M, et al. Chronic obstructive pulmonary disease. Lancet. 2022;399(10342):2227–2242. doi:10.1016/s0140-6736(22)00470-6
   PubMed Web of Science ®Google Scholar
• Majid H, Kanbar-Agha F, Sharafkhaneh A. COPD: osteoporosis and sarcopenia. COPD Res Pract. 2016;2(1):3. doi:10.1186/s40749-016-0019-0
   Google Scholar
• Mollica M, Aronne L, Paoli G, et al. Elderly with COPD: comoborbitidies and systemic consequences. J Gerontol Geriatr. 2021;69(1):32–44. doi:10.36150/2499-6564-434
   Web of Science ®Google Scholar
• Cruz-Jentoft AJ, Sayer AA. Sarcopenia. Lancet. 2019;393(10191):2636–2646. doi:10.1016/s0140-6736(19)31138-9
   PubMed Web of Science ®Google Scholar
• Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16–31. doi:10.1093/ageing/afy169
   PubMed Web of Science ®Google Scholar
• Chen LK, Woo J, Assantachai P, et al. Asian working group for sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc. 2020;21(3):300–07.e2. doi:10.1016/j.jamda.2019.12.012
   PubMed Web of Science ®Google Scholar
• Petermann-Rocha F, Balntzi V, Gray SR, et al. Global prevalence of sarcopenia and severe sarcopenia: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2022;13(1):86–99. doi:10.1002/jcsm.12783
   PubMed Web of Science ®Google Scholar
• Nicholson JM, Orsso CE, Nourouzpour S, et al. Computed tomography-based body composition measures in COPD and their association with clinical outcomes: a systematic review. Chron Respir Dis. 2022;19:14799731221133387. doi:10.1177/14799731221133387
   Web of Science ®Google Scholar
• Pishgar F, Shabani M, Silva TQAC, et al. Quantitative analysis of adipose depots by using chest CT and associations with all-cause mortality in chronic obstructive pulmonary disease: longitudinal analysis from MESArthritis ancillary study. Radiology. 2021;299(3):703–711. doi:10.1148/radiol.2021203959
   PubMed Web of Science ®Google Scholar
• Jaitovich A, Barreiro E. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. what we know and can do for our patients. Am J Respir Crit Care Med. 2018;198(2):175–186. doi:10.1164/rccm.201710-2140CI
   PubMed Web of Science ®Google Scholar
• Bui K-L, Nyberg A, Rabinovich R, Saey D, Maltais F. The relevance of limb muscle dysfunction in chronic obstructive pulmonary disease: a review for clinicians. Clin Chest Med. 2019;40(2):367–383. doi:10.1016/j.ccm.2019.02.013
   PubMed Web of Science ®Google Scholar
• Taivassalo T, Hepple RT. Integrating mechanisms of exacerbated atrophy and other adverse skeletal muscle impact in COPD. Front Physiol. 2022;13:861617. doi:10.3389/fphys.2022.861617
   PubMed Web of Science ®Google Scholar
• Benz E, Trajanoska K, Lahousse L, et al. Sarcopenia in COPD: a systematic review and meta-analysis. Eur Respir Rev. 2019;28(154):190049. doi:10.1183/16000617.0049-2019
   PubMed Web of Science ®Google Scholar
• He J, Li H, Yao J, Wang Y. Prevalence of sarcopenia in patients with COPD through different musculature measurements: an updated meta-analysis and meta-regression. Front Nutr. 2023;10:1137371. doi:10.3389/fnut.2023.1137371
   PubMed Web of Science ®Google Scholar
• Wu D, Chen Q. Diagnosis and treatment of chronic obstructive pulmonary disease-related sarcopenia. Parenteral Enteral Nutr. 2021;28(5):308–312.
   Google Scholar
• Wang P, Zhang S, Zhang X, Liu Y, Sun J. Exploring the pathogenesis of chronic obstructive pulmonary disease complicated with sarcopenia based on the theory of Pi Governing Muscles. Chin J Integrated Tradit Western Med. 2023;43(1):107–112.
   Google Scholar
• Gu W, Li X, Zhong X, Zhou D. Research progress on relationship between skeletal muscle atrophy and apoptosis in COPD based on theory of spleen dominating muscles and intervention effect of traditional Chinese medicine. Shanghai J Tradit Chin Med. 2023;57(1):100–104.
   Google Scholar
• Chaomei C. Science mapping: a systematic review of the literature. J Data Inf Sci. 2017;2(2):1–40.
   Google Scholar
• Nees Jan van Eck LW, Waltman L. Software survey: vOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84(2):523–538. doi:10.1007/s11192-009-0146-3
   PubMed Web of Science ®Google Scholar
• Yang Y, Chen Y, Liu Y, et al. Mesenchymal stem cells and pulmonary fibrosis: a bibliometric and visualization analysis of literature published between 2002 and 2021. Front Pharmacol. 2023;14(113676). doi:10.3389/fphar.2023.1136761
   Google Scholar
• Xu D, Wang Y-L, Wang K-T, et al. A scientometrics analysis and visualization of depressive disorder. Curr Neuropharmacol. 2021;19(6):766–786. doi:10.2174/1570159x18666200905151333
   PubMed Web of Science ®Google Scholar
• van Bakel SIJ, Gosker HR, Langen RC, Amwj S. Towards personalized management of sarcopenia in COPD. Int J Chron Obstruct Pulmon Dis. 2021;16:25–40. doi:10.2147/copd.S280540
   PubMed Web of Science ®Google Scholar
• Karim A, Muhammad T, Iqbal MS, Qaisar R. A multistrain probiotic improves handgrip strength and functional capacity in patients with COPD: a randomized controlled trial. Arch Gerontol Geriatr. 2022;102:104721. doi:10.1016/j.archger.2022.104721
   PubMed Web of Science ®Google Scholar
• Nan Y, Zhou Y, Dai Z, et al. Role of nutrition in patients with coexisting chronic obstructive pulmonary disease and sarcopenia. Front Nutri. 2023;10:1214684. doi:10.3389/fnut.2023.1214684
   PubMed Web of Science ®Google Scholar
• Brunton NM, Barbour DJ, Gelinas JC, et al. Lower-limb resistance training reduces exertional dyspnea and intrinsic neuromuscular fatigability in individuals with chronic obstructive pulmonary disease. J Appl Physiol. 2023;134(5):1105–1114. doi:10.1152/japplphysiol.00303.2022
   PubMed Web of Science ®Google Scholar
• Ravelo D, Yair D, Wiese P, et al. Blood flow restriction training improves pulmonary function in a patient with COPD and sarcopenia [abstract]. Cardiopul Phy Therap J. 2023;34(1):a13. doi:10.1097/CPT.0000000000000220
   Google Scholar
• Marquis K, Debigaré R, Lacasse Y, et al. Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;166(6):809–813. doi:10.1164/rccm.2107031
   PubMed Web of Science ®Google Scholar
• Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people. Age Ageing. 2010;39(4):412–423. doi:10.1093/ageing/afq034
   PubMed Web of Science ®Google Scholar
• Schols AM, Broekhuizen R, Weling-Scheepers CA, Wouters EF. Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr. 2005;82(1):53–59. doi:10.1093/ajcn.82.1.53
   PubMed Web of Science ®Google Scholar
• Swallow EB, Reyes D, Hopkinson NS, et al. Quadriceps strength predicts mortality in patients with moderate to severe chronic obstructive pulmonary disease. Thorax. 2007;62(2):115–120. doi:10.1136/thx.2006.062026
   PubMed Web of Science ®Google Scholar
• Jones SE, Maddocks M, Kon SS, et al. Sarcopenia in COPD: prevalence, clinical correlates and response to pulmonary rehabilitation. Thorax. 2015;70(3):213–218. doi:10.1136/thoraxjnl-2014-206440
   PubMed Web of Science ®Google Scholar
• Bernard S, LeBlanc P, Whittom F, et al. Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;158(2):629–634. doi:10.1164/ajrccm.158.2.9711023
   PubMed Web of Science ®Google Scholar
• Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. New Engl J Med. 2004;350(10):1005–1012. doi:10.1056/NEJMoa021322
   PubMed Web of Science ®Google Scholar
• Schols AM, Slangen J, Volovics L, Wouters EF. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(6 Pt 1):1791–1797. doi:10.1164/ajrccm.157.6.9705017
   PubMed Web of Science ®Google Scholar
• Crapo RO, Casaburi R, Coates AL, et al. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111–117. doi:10.1164/rccm.166/1/111
   PubMed Web of Science ®Google Scholar
• Maltais F, Decramer M, Casaburi R, et al. An official American thoracic society/European respiratory society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2014;189(9):e15–62. doi:10.1164/rccm.201402-0373ST
   PubMed Web of Science ®Google Scholar
• Landbo C, Prescott E, Lange P, Vestbo J, Almdal TP. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160(6):1856–1861. doi:10.1164/ajrccm.160.6.9902115
   PubMed Web of Science ®Google Scholar
• Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176(6):532–555. doi:10.1164/rccm.200703-456SO
   PubMed Web of Science ®Google Scholar
• Vestbo J, Prescott E, Almdal T, et al. Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample - findings from the Copenhagen City Heart Study. Am J Respir Crit Care Med. 2006;173(1):79–83. doi:10.1164/rccm.200505-969OC
   PubMed Web of Science ®Google Scholar
• Gosselink R, Troosters T, Decramer M. Peripheral muscle weakness contributes to exercise limitation in COPD. Am J Respir Crit Care Med. 1996;153(3):976–980. doi:10.1164/ajrccm.153.3.8630582
   PubMed Web of Science ®Google Scholar
• Doucet M, Russell AP, Leger B, et al. Muscle atrophy and hypertrophy signaling in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;176(3):261–269. doi:10.1164/rccm.200605-704OC
   PubMed Web of Science ®Google Scholar
• Steiner MC, Barton RL, Singh SJ, Morgan MDL. Bedside methods versus dual energy X-ray absorptiometry for body composition measurement in COPD. Eur Respir J. 2002;19(4):626–631. doi:10.1183/09031936.02.00279602
   PubMed Web of Science ®Google Scholar
• Miller MR. General considerations for lung function testing. Eur Respir J. 2005;26(1):153–161. doi:10.1183/09031936.05.00034505
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33(5):1165–1185. doi:10.1183/09031936.00128008
   PubMed Web of Science ®Google Scholar
• Shrikrishna D, Patel M, Tanner RJ, et al. Quadriceps wasting and physical inactivity in patients with COPD. Eur Respir J. 2012;40(5):1115–1122. doi:10.1183/09031936.00170111
   PubMed Web of Science ®Google Scholar
• Seymour JM, Spruit MA, Hopkinson NS, et al. The prevalence of quadriceps weakness in COPD and the relationship with disease severity. Eur Respir J. 2010;36(1):81–88. doi:10.1183/09031936.00104909
   PubMed Web of Science ®Google Scholar
• Whittom F, Jobin J, Simard PM, et al. Histochemical and morphological characteristics of the vastus lateralis muscle in patients with chronic obstructive pulmonary disease. Med Sci Sports Exerc. 1998;30(10):1467–1474. doi:10.1097/00005768-199810000-00001
   PubMed Web of Science ®Google Scholar
• Bodine SC, Latres E, Baumhueter S, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science. 2001;294(5547):1704–1708. doi:10.1126/science.1065874
   PubMed Web of Science ®Google Scholar
• Sandri M, Sandri C, Gilbert A, et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell. 2004;117(3):399–412. doi:10.1016/s0092-8674(04)00400-3
   PubMed Web of Science ®Google Scholar
• Plant PJ, Brooks D, Faughnan M, et al. Cellular markers of muscle atrophy in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2010;42(4):461–471. doi:10.1165/rcmb.2008-0382OC
   PubMed Web of Science ®Google Scholar
• Gosker HR, Zeegers MP, Wouters EFM, Amwj S. Muscle fibre type shifting in the vastus lateralis of patients with COPD is associated with disease severity: a systematic review and meta-analysis. Thorax. 2007;62(11):944–949. doi:10.1136/thx.2007.078980
   PubMed Web of Science ®Google Scholar
• Mostert R, Goris A, Weling-Scheepers C, Wouters EFM, Schols A. Tissue depletion and health related quality of life in patients with chronic obstructive pulmonary disease. Respir Med. 2000;94(9):859–867. doi:10.1053/rmed.2000.0829
   PubMed Web of Science ®Google Scholar
• Evans WJ, Morley JE, Argiles J, et al. Cachexia: a new definition. Clin Nutr. 2008;27(6):793–799. doi:10.1016/j.clnu.2008.06.013
   PubMed Web of Science ®Google Scholar
• Schols AM, Soeters PB, Dingemans AM, Mostert R, Frantzen PJ, Wouters EF. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis. 1993;147(5):1151–1156. doi:10.1164/ajrccm/147.5.1151
   PubMed Web of Science ®Google Scholar
• Byun MK, Cho EN, Chang J, Ahn CM, Kim HJ. Sarcopenia correlates with systemic inflammation in COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:669–675. doi:10.2147/copd.S130790
   PubMed Web of Science ®Google Scholar
• Fermoselle C, Rabinovich R, Ausin P, et al. Does oxidative stress modulate limb muscle atrophy in severe COPD patients? Eur Respir J. 2012;40(4):851–862. doi:10.1183/09031936.00137211
   PubMed Web of Science ®Google Scholar
• Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347–365. doi:10.1164/rccm.201204-0596PP
   PubMed Web of Science ®Google Scholar
• Mador MJ, Bozkanat E. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. Respir Res. 2001;2(4):216–224. doi:10.1186/rr60
   PubMed Web of Science ®Google Scholar
• Jagoe RT, Engelen M. Muscle wasting and changes in muscle protein metabolism in chronic obstructive pulmonary disease. Eur Respir J. 2003;22:52S–63S. doi:10.1183/09031936.03.00004608
   Web of Science ®Google Scholar
• O’Brien ME, Hyre N, Leader JK, Chandra D, Sciurba FC, Bon J. Chest ct pectoralis muscle size validated with dual energy X-ray absorptiometry measurements of body composition is associated with lung function in COPD [abstract]. Am J Respir Crit Care Med. 2018;197:1.
   PubMed Web of Science ®Google Scholar
• Cao J, Zuo D, Han T, et al. Correlation between bioelectrical impedance analysis and chest CT-measured erector spinae muscle area: a cross-sectional study. Front Endocrinol. 2022;13:923200. doi:10.3389/fendo.2022.923200
   PubMed Web of Science ®Google Scholar
• Attaway A, Welch N, Yadav R, et al. Quantitative CT assessment of pectoralis and erector spinae muscle area and disease severity in COPD [abstract]. Am J Respir Crit Care Med. 2021;203(9). doi:10.1164/ajrccm-conference.2021.203.1_MeetingAbstracts.A2289
   Web of Science ®Google Scholar
• O’Brien ME, Zou RH, Hyre N, et al. CT pectoralis muscle area is associated with DXA lean mass and correlates with emphysema progression in a tobacco-exposed cohort. Thorax. 2023;78(4):394–401. doi:10.1136/thoraxjnl-2021-217710
   PubMed Web of Science ®Google Scholar
• Maetani T, Tanabe N, Shiraishi Y, et al. Centrilobular emphysema is associated with pectoralis muscle reduction in current smokers without airflow limitation. Respiration. 2023;102(3):194–202. doi:10.1159/000529031
   PubMed Web of Science ®Google Scholar
• Brath MS, Sahakyan M, Veiss-Pedersen P, et al. Contrast enhanced computed tomography based cumulated thoracic muscular cross- sectional area and the correlation to single muscle groups of the thorax; pectoralis, latissimus dorsi, and spinae erector muscles in patients without chronic diseases, a pilot study [abstract]. Am J Respir Crit Care Med. 2022;205(1). doi:10.1164/ajrccm-conference.2022.205.1_MeetingAbstracts.A3791
   Google Scholar
• Garcha PS, Nisar T, Jamil AK, et al. Single-center study evaluating the impact of sarcopenia on outcomes after lung transplantation. J Heart Lung Transplant. 2019;38(Suppl 4):S333–S34. doi:10.1016/j.healun.2019.01.842
   Web of Science ®Google Scholar
• Frille A, Linder N, Busse H, et al. Brown adipose tissue activation quantified by positron emission tomography/computed tomography describes pulmonary cachexia in COPD patients. NuklearMedizin. 2019;58(2):187. doi:10.1055/s-0039-1683719
   Google Scholar
• Vellas B, Fielding R, Bhasin S, et al. Sarcopenia trials in specific diseases: report by the international conference on frailty and sarcopenia research task force. J Frailty Aging. 2016;5(4):194–200. doi:10.14283/jfa.2016.110
   PubMedGoogle Scholar
• Limpawattana P, Putraveephong S, Inthasuwan P, Boonsawat W, Theerakulpisut D, Chindaprasirt J. Frailty syndrome in ambulatory patients with COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:1193–1198. doi:10.2147/COPD.S134233
   PubMed Web of Science ®Google Scholar
• Celis Preciado CA, Borda M, Castelblanco S, et al. Sarcopenia and frailty, two new domains in chronic obstructive pulmonary disease prognosis: a systematic review. Am J Respir Crit Care Med. 2017;195:1.
   Web of Science ®Google Scholar
• Mason SE, Moreta-Martinez R, Labaki WW, et al. Longitudinal association between muscle loss and mortality in ever smokers. Chest. 2022;161(4):960–970. doi:10.1016/j.chest.2021.10.047
   PubMed Web of Science ®Google Scholar
• Byrne T, Cooke J, Bambrick P, McNeela E, Harrison M. Circulating inflammatory biomarker responses in intervention trials in frail and sarcopenic older adults: a systematic review and meta-analysis. Exp Gerontol. 2023;177:112199. doi:10.1016/j.exger.2023.112199
   PubMed Web of Science ®Google Scholar
• Chen YW, Ramsook AH, Coxson HO, Bon J, Reid WD. Prevalence and risk factors for osteoporosis in individuals with COPD: a systematic review and meta-analysis. Chest. 2019;156(6):1092–1110. doi:10.1016/j.chest.2019.06.036
   PubMed Web of Science ®Google Scholar
• Zhang L, Sun Y. Muscle-bone crosstalk in chronic obstructive pulmonary disease. Front Endocrinol. 2021;12:724911. doi:10.3389/fendo.2021.724911
   PubMed Web of Science ®Google Scholar
• Sun Y, Zhang L, Cai H, Chen Y. Editorial: osteoporosis, sarcopenia and muscle-bone crosstalk in COPD. Front Physiol. 2022;13:1040693. doi:10.3389/fphys.2022.1040693
   PubMed Web of Science ®Google Scholar
• Suleymanova AK, Baranova IA. Osteosarcopenia and severe osteosarcopenia in COPD patients. Osteoporos Int. 2020;31(suppl 1):S277–S78. doi:10.1007/s00198-020-05696-3
   PubMed Web of Science ®Google Scholar
• Lee D, Kim J. Similarities and differences in the effects of sarcopenia on bone mineral density reduction between mild chronic chronic obstructive pulmonary disease (COPD), moderate to severe COPD and normal lung function in the elderly. Am J Respir Crit Care Med. 2020;201(1):1.
   PubMedGoogle Scholar
• Wilson AC, Bon JM, Mason S, et al. Increased chest CT derived bone and muscle measures capture markers of improved morbidity and mortality in COPD. Respir Res. 2022;23(1):311. doi:10.1186/s12931-022-02237-w
   PubMed Web of Science ®Google Scholar
• Wilson AC, Bon J, Mason S, et al. Increased bone and muscle measures derived from chest CT are markers of improved quality of life, function, and survival in COPD [abstract]. Am J Respir Crit Care Med. 2021;203(9):1.
   PubMed Web of Science ®Google Scholar
• Kelly OJ, Gilman JC, Boschiero D, Ilich JZ. Osteosarcopenic obesity: current knowledge, revised identification criteria and treatment principles. Nutrients. 2019;11(4):747. doi:10.3390/nu11040747
   PubMed Web of Science ®Google Scholar
• Liu Y, Song Y, Hao Q, Wu J. Global prevalence of osteosarcopenic obesity amongst middle aged and older adults: a systematic review and meta-analysis. Arch Osteoporos. 2023;18(1):60. doi:10.1007/s11657-023-01247-5
   PubMed Web of Science ®Google Scholar
• Lippi L, Folli A, Curci C, et al. Osteosarcopenia in patients with chronic obstructive pulmonary diseases: which pathophysiologic implications for rehabilitation? Int J Env Res Public Health. 2022;19(21):14314. doi:10.3390/ijerph192114314
   PubMed Web of Science ®Google Scholar
• Kim SH, Shin MJ, Shin YB, Kim KU. Sarcopenia associated with chronic obstructive pulmonary disease. J Bone Metab. 2019;26(2):65–74. doi:10.11005/jbm.2019.26.2.65
   PubMedGoogle Scholar
• Lakhdar R, Rabinovich RA. Can muscle protein metabolism be specifically targeted by nutritional support and exercise training in chronic obstructive pulmonary disease? J Thorac Dis. 2018;10:S1377–S89. doi:10.21037/jtd.2018.05.81
   PubMed Web of Science ®Google Scholar
• Jang YJ. The effects of protein and supplements on sarcopenia in human clinical studies: how older adults should consume protein and supplements. J Microbiol Biotechnol. 2023;33(2):143–150. doi:10.4014/jmb.2210.10014
   PubMed Web of Science ®Google Scholar
• Piscaer I, Janssen R, Franssen FME, Schurgers LJ, Wouters EFM. The pleiotropic role of vitamin K in multimorbidity of chronic obstructive pulmonary disease. J Clin Med. 2023;12(4)::1261. doi:10.3390/jcm12041261
   PubMed Web of Science ®Google Scholar
• Cornelison SD, Pascual RM. Pulmonary rehabilitation in the management of chronic lung disease. Med Clin North Am. 2019;103(3):577–584. doi:10.1016/j.mcna.2018.12.015
   PubMed Web of Science ®Google Scholar
• Shen Y, Shi Q, Nong K, et al. Exercise for sarcopenia in older people: a systematic review and network meta-analysis. J Cachexia Sarcopenia Muscle. 2023;14(3):1199–1211. doi:10.1002/jcsm.13225
   PubMed Web of Science ®Google Scholar